+Compare
CORT
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
2.7B

CORT Corcept Therapeutics Forecast, Technical & Fundamental Analysis

a maker of drugs for the treatment of severe psychiatric and neurological diseases

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for CORT with price predictions
08:00 PM EDT Oct 02, 2023

CORT in downward trend: 10-day moving average moved below 50-day moving average on October 03, 2023

The 10-day moving average for CORT crossed bearishly below the 50-day moving average on October 03, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 21, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on CORT as a result. In of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

CORT moved below its 50-day moving average on September 29, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CORT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CORT advanced for three days, in of 313 cases, the price rose further within the following month. The odds of a continued upward trend are .

CORT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 243 cases where CORT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CORT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.394) is normal, around the industry mean (22.791). P/E Ratio (32.468) is within average values for comparable stocks, (131.379). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.084). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (7.037) is also within normal values, averaging (309.467).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.17B. The market cap for tickers in the group ranges from 402 to 403.32B. NVO holds the highest valuation in this group at 403.32B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was 16%, and the average quarterly price growth was 21%. BNOX experienced the highest price growth at 337%, while RGMP experienced the biggest fall at -72%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was 139% and the average quarterly volume growth was 150%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

CORT is expected to report earnings to fall 16.24% to 20 cents per share on November 02

Corcept Therapeutics CORT Stock Earnings Reports
Q3'23
Est.
$0.21
Q2'23
Beat
by $0.10
Q1'23
Missed
by $0.05
Q4'22
Missed
by $0.10
Q3'22
Beat
by $0.07
The last earnings report on August 02 showed earnings per share of 25 cents, beating the estimate of 15 cents. With 75.39K shares outstanding, the current market capitalization sits at 2.70B.
A.I. Advisor
published General Information

General Information

a maker of drugs for the treatment of severe psychiatric and neurological diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
149 Commonwealth Drive
Phone
+1 650 327-3270
Employees
299
Web
https://www.corcept.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VIXM20.451.07
+5.52%
ProShares VIX Mid-Term Futures
GTO43.95-0.38
-0.86%
Invesco Total Return Bond ETF
BNOV32.28-0.43
-1.31%
Innovator US Equity Buffer ETF Nov
ERSX11.36-0.22
-1.93%
ERShares NextGen Entrepreneurs ETF
RFV95.33-2.28
-2.34%
Invesco S&P MidCap 400® Pure Value ETF

CORT and

Correlation & Price change

A.I.dvisor indicates that over the last year, CORT has been loosely correlated with INVA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CORT jumps, then INVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CORT
1D Price
Change %
CORT100%
-0.46%
INVA - CORT
39%
Loosely correlated
-0.46%
BMRN - CORT
39%
Loosely correlated
-1.03%
CAPR - CORT
37%
Loosely correlated
-2.02%
ATAI - CORT
36%
Loosely correlated
+12.10%
AXON - CORT
36%
Loosely correlated
-2.09%
More

Groups containing CORT

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CORT
1D Price
Change %
CORT100%
-0.46%
psychiatric
(undefined stocks)
97%
Closely correlated
-3.96%
treatment
(undefined stocks)
39%
Loosely correlated
-1.86%
drugs
(undefined stocks)
36%
Loosely correlated
-1.36%
pharmaceuticals
(undefined stocks)
33%
Loosely correlated
-0.53%
neurological
(undefined stocks)
17%
Poorly correlated
-1.66%